Back to discover
Drug

Adebrelimab

Approved medicine
ClassProgrammed cell death 1 ligand 1 inhibitorResearchOngoing clinical research

Also known as 阿得贝利单抗, Adebelizumab.

RxNorm2471561ChEMBLCHEMBL4297828UNII1XBY50W1OX
108
Active clinical trials
Programmed cell death 1 ligand 1
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multi-cohort, Multi-center Phase II Clinical Study of Adebrelimab in Combination With SHR-A1811/SHR-A1904 and Chemotherapy or Adebrelimab in Combination With SHR-8068 as the Treatment in Subjects With Gastric or Gastroesophageal Junction Cancer

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A Multicenter, Open-label Phase Ib/II Clinical Trial of SHR-A2102 Injection in Combination With Adebrelimab Injection, With or Without Other Anti-tumor Therapies, in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Clinical trial2026-07-20Results expected Q1 2027 · ClinicalTrials.gov

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma: a Single-arm, Multicenter, Phase II Clinical Study

Clinical trial2026-07-13Primary completion · ClinicalTrials.gov

A Randomized, Open-label, Multicenter Phase II Study of SHR-8068 Combined With Adebrelimab and Apatinib for Perioperative Treatment in Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk

Clinical trial2026-07-02Results expected Q3 2027 · ClinicalTrials.gov

A Phase III, Multicenter, Randomized, Open-Label Parallel-Controlled Study of Trastuzumab Rezetecan (SHR-A1811) in Combination With Adebrelimab (SHR-1316) Versus Investigator's Choice of Therapy in Subjects With Primary Triple Negative Breast Cancer Who Have Residual Invasive Disease Following Neoadjuvant Therapy

Clinical trial2026-07-01Results expected Q4 2030 · ClinicalTrials.gov

Selinexor Combined With Nab-paclitaxel and Adebrelimab as Second-line Treatment for ES-SCLC：A Prospective, Single-center, Single-arm Clinical Study

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung Cancer

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

An Open-label, Multicenter Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

Efficacy and Safety of Stereotactic Body Radiotherapy Followed by Adebrelimab and Lenvatinib for Hepatocellular Carcinoma With Abdominal Lymph Node Metastases: A Two-arm, Phase II Trial

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

A Prospective, Open-label, Multicenter Phase II Clinical Study of Rikang Trastuzumab in Combination With Adebrelimab and Lenvatinib for First-line Treatment of HER2-positive or Low-expressing Locally Advanced or Metastatic Biliary Tract Cancer

Clinical trial2026-06-26Results expected Q2 2027 · ClinicalTrials.gov

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)

Clinical trial2026-03-04Trial news · Journal of Clinical Oncology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Adebrelimab
Aliases & brands
阿得贝利单抗Adebelizumab
RxNorm CUI
2471561
ChEMBL ID
CHEMBL4297828
UNII
1XBY50W1OX
Primary mechanism
Programmed cell death 1 ligand 1 inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Programmed cell death 1 ligand 1
CD274 · Q9NZQ7
INHIBITORProgrammed cell death 1 ligand 1 inhibitor

Clinical trials

114 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
114
registered trials across all phases
108
Active studies
106
Recruiting
10
Late-stage (III+)
6
Discontinued
PHASE DISTRIBUTIONn = 114
Early Phase 12Phase 18Phase 1 / 213Phase 281Phase 36Phase N / A4

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Phase III, Multicenter, Randomized, Open-Label Parallel-Controlled Study of Trastuzumab Rezetecan (SHR-A1811) in Combination With Adebrelimab (SHR-1316) Versus Investigator's Choice of Therapy in Subjects With Primary Triple Negative Breast Cancer Who Have Residual Invasive Disease Following Neoadjuvant Therapy

Not yet recruitingPH IIIKey trialSuzhou Suncadia Biopharmaceuticals Co., Ltd.n=1,0002032

Multicenter, Prospective Phase III Clinical Trial of EBV-DNA-Guided Adaptive Immunotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Not yet recruitingPH IIISun Yat-sen Universityn=5162031

A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Study of Anti CTLA-4 Antibody SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma

RecruitingPH IIISuzhou Suncadia Biopharmaceuticals Co., Ltd.n=5902030

A Phase III, Randomized, Controlled, Open-Label, Multicenter Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-Line Treatment for Advanced Biliary Tract Cancer (BTC)

RecruitingPH IIISuzhou Suncadia Biopharmaceuticals Co., Ltd.n=6042029

Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC: a Randomized Controlled Phase III Clinical Study

Not yet recruitingPH IIIJinming Yun=5242029
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials